Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan–human epidermal growth factor receptor inhibitor, versus erlotinib in patients with …
SS Ramalingam, F Blackhall, M Krzakowski… - Journal of clinical …, 2012 - ascopubs.org
Purpose This randomized, open-label trial compared dacomitinib (PF-00299804), an
irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and …
irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and …
Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With …
SS Ramalingam, F Blackhall, M Krzakowski… - Journal of Clinical …, 2012 - cir.nii.ac.jp
< jats: sec>< jats: title> Purpose</jats: title>< jats: p> This randomized, open-label trial
compared dacomitinib (PF-00299804), an irreversible inhibitor of human epidermal growth …
compared dacomitinib (PF-00299804), an irreversible inhibitor of human epidermal growth …
Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With …
SS Ramalingam, F Blackhall… - JOURNAL OF …, 2012 - scholarworks.bwise.kr
Purpose This randomized, open-label trial compared dacomitinib (PF-00299804), an
irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and …
irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and …
[HTML][HTML] Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in …
SS Ramalingam, F Blackhall… - Journal of Clinical …, 2012 - ncbi.nlm.nih.gov
Purpose This randomized, open-label trial compared dacomitinib (PF-00299804), an
irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and …
irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and …
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with …
SS Ramalingam, F Blackhall… - Journal of Clinical …, 2012 - snucm.elsevierpure.com
Purpose: This randomized, open-label trial compared dacomitinib (PF-00299804), an
irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and …
irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and …
[PDF][PDF] Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients …
SS Ramalingam, F Blackhall, M Krzakowski… - Medical …, 2010 - researchgate.net
Purpose This randomized, open-label trial compared dacomitinib (PF-00299804), an
irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and …
irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and …
[PDF][PDF] Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients …
SS Ramalingam, F Blackhall, M Krzakowski… - Medical …, 2010 - academia.edu
Purpose This randomized, open-label trial compared dacomitinib (PF-00299804), an
irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and …
irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and …
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with …
S Ramalingam, F Blackhall, M Krzakowski… - Journal of clinical …, 2012 - ora.ox.ac.uk
PURPOSE: This randomized, open-label trial compared dacomitinib (PF-00299804), an
irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and …
irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and …
Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With …
SS Ramalingam, FH Blackhall, M Krzakowski… - 2012 - christie.openrepository.com
PURPOSE This randomized, open-label trial compared dacomitinib (PF-00299804), an
irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and …
irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and …
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with …
SS Ramalingam, F Blackhall… - Journal of …, 2012 - mdanderson.elsevierpure.com
Purpose: This randomized, open-label trial compared dacomitinib (PF-00299804), an
irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and …
irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and …